You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The funding will be used to provide free at-home DNA tests to individuals with Long COVID, as well as to advance Sano's data-sharing platform.
The company, known for providing hereditary risk testing for cancer and cardiovascular conditions, has expanded into SARS-CoV-2 testing.
The genetic test is currently under review by the US Food and Drug Administration, which granted it a breakthrough device designation in 2018.
HeartGenetics offers a range of genetic tests and services including ones for general wellness, cardiovascular conditions, and pharmacogenetics.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.
Jackson Laboratory researchers will lead an interdisciplinary team of experts to study the employee health benefits of workplace genetic testing.
The drugmaker has a small molecule drug called venglustat under Phase II development for Parkinson's disease patients with a specific genetic mutation.
In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.